Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The treatment of isolated distal deep vein thrombosis remains one of the most debated issues
in the field of venous thromboembolism and only very few studies have directly addressed the
issue of treatment in objectively confirmed isolated distal deep vein thrombosis. Aim of this
study is to assess the long-term risk of recurrent venous thrombotic events in patients with
a first acute symptomatic isolated distal deep vein thrombosis of the leg treated with a
standard (12 weeks) or with a shorter (6 weeks) duration of therapy with rivaroxaban.